Table 8.

Lipid outcomes in the Kipnes trial29

	Fenofibric acid + rosuvastatin 20 mg
HDL-C n = 161
Baseline mean (mg/dL)	38.3
Final mean at 116 weeks (mg/dL)	45.0
Mean percent change from baseline (%) ± SD	19.2 ± 25.23
TG n = 161
Baseline mean (mg/dL)	294.5
Final mean at 116 weeks (mg/dL)	137.5
Mean percent change from baseline (%) ± SD	−48.2 ± 22.61
LDL-C n = 159
Baseline mean (mg/dL)	152.5
Final mean at 116 weeks (mg/dL)	87.0
Mean percent change from baseline (%) ± SD	−40.9 ± 20.66
Non-HDL-C n = 161
Baseline mean (mg/dL)	222.6
Final mean at 116 weeks (mg/dL)	113.2
Mean percent change from baseline (%) ± SD	−48.6 ± 13.58
VLDL-C n = 152
Baseline mean (mg/dL)	71.4
Final mean at 116 weeks (mg/dL)	26.6
Mean percent change from baseline (%) ± SD	−56.8 ± 25.17
Total-C n = 161
Baseline mean (mg/dL)	260.9
Final mean at 116 weeks (mg/dL)	158.1
Mean percent change from baseline (%) ± SD	−38.7 ± 12.16

Abbreviations: HDL-C, high-density lipoprotein-cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; non-HDL-C, non high-density lipoprotein-cholesterol; VLDL-C, very-low density lipoprotein-cholesterol; total-C, total cholesterol.